‘That model is not sustainable’: Pharma giants AstraZeneca and Merck are sounding the alarm on the middlemen who stand between drug makers and patients
|10/22/2018||Posted by BusinessMediaguide.Com under General World News||
- Drug pricing remains an issue facing the healthcare industry, though little has been done to curb it.
- Pharma executives, including AstraZeneca US president Ruud Dobber and Merck CEO Kenneth Frazier are starting to get fed up, particularly with the role so-called middlemen play.
- For now, it’s unclear where the rebates pharmaceutical companies pay out end up. “That model is not sustainable,” Dobber said.
Rising drug prices have been at the center of American conversation for the past three years.